| Recurrent ovarian cancer always is treated with chemotherapy or secondary tumor mainly to destroy loss,but the treatment effect is not ideal,with the advent of precision medical,the molecular targeted drugs become a new choice for the treatment,targeted drug PARPi showed significant effect in the clinical trials,It has now been approved for clinical application.The homologous recombination deficiency(HRD)and platinum-sensitive patients are the most benefit,significantly prolong the progression-free survival(PFS)of patients.This article reviews the mechanism of PARPi,the application of population,the latest development of clinical trials,adverse reactions and curative effect prediction markers,so as to provide some guidance for its clinical application. |
PDF Full Text Request